Cathepsin D versus other prognostic factors in breast cancer. Results and controversies of a multicenter study on 2575 cases

International Journal of Biological Markers

Volumn 11, Issue 3, 1996, Pages 139-147

  Pelizzola, D ^a   Gion, M ^b   Paradiso, A ^c   Dittadi, R ^b   Correale, M ^c   Mione, R ^b   Piffanelli, A ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Ctro Regionale Indicatori BT   (Italy)

^c Lab di Oncol Clinica Sperimentale   (Italy)

Author keywords

Breast cancer ER; Cathepsin D; PgR; Prognostic factors

Indexed keywords

CATHEPSIN D; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; CYTOSOL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; PROGNOSIS; QUALITY CONTROL; RETROSPECTIVE STUDY;

EID: 0029852921     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089601100301     Document Type: Article

References (38)

1. Westley B, Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 1980; 20: 353-62.
2. Rochefort H, Augereau P, Briozzo P, et al. Structure, function, regulation and clinical significance of 52k procathepsin D secreted by breast cancer cells. Biochimie 1988; 70: 943-9.
3. Freiss G, Vignon F, Rochefort H. Characterization and properties of two MAbs specific for the M dr 52,000 precursor of cathepsin D in human breast cancer cells. Cancer Res 1988; 48: 3709-15.
4. Freiss G, Vignon F, Pau B, et al. A two-site immunoenzymometric assay of 52 kD pro-cathepsin D and its use in human breast diseases. Clin Chem 1989; 35 (2): 234-7.
5. Garcia M, Lacombe MJ, Duplay H, et al. Immunohistochemical distribution of the 52kDa protein in mammary tumors: a marker associated with cell proliferation rather than with hormone responsiveness. J Steroid Biochem 1987; 27 (1-3): 435-45.
6. Cavailles V, Augereau P, Garcia M, Rochefort H. Estrogens and growth factors induce the mRNA of the 52k-pro-cathepsin D secreted by breast cancer cells. Nucleic Acids Res 1988; 16: 1903-19.
7. Rochefort H, Capony F, Garcia M, et al. Estrogen-induced lysosomal protease secreted by breast cancer cells. A role in carcinogenesis? J Cell Biochem 1987; 35: 17-29.
8. Vignon F, Capony F, Chambon M, Freiss G, Garcia M, Rochefort H. Autocrine growth stimulation of the MCF breast cancer cells by the estrogen-regulated 52K protein. Endocrinology 1986; 118: 1537-45.
9. Briozzo P, Morisset M, Capony F, Rougeot C, Rochefort H. In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res 1988; 48: 3688-92.
10. Thorpe S, Rochefort H, Garcia M, et al. Association between high concentration of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Anticancer Res 1989; 49: 6008-14.
11. Spyratos F, Brouillet J-P, Defrenne A, et al. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 1989; 1: 1115-8.
12. Tandon AK, Clark GM, Chamnes GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990; 332: 297-302.
13. Romain S, Muracciole X, Varette I, Bressac C, Brandone H, Martin PM. La cathepsin-D: un facteur pronostique independant dans la cancer du sein. Bull Cancer 1990; 77: 439-47.
14. Granata G, Coradini D, Cappelletti V, Di Fronzo G. Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer 1991; 27 (8): 970-2.
15. Namer M, Ramaioli A, Fontana X, et al. Prognostic value of total cathepsin D in breast tumors. Breast Cancer Res Treat 1991; 19: 85-93.
16. Duffy MJ, Reilly D, Brouillet J-P, et al. Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival. Clin Chem 1992; 38 (10): 2114-6.
17. Domagala W, Striker G, Szadowska A, Dukowicz A, Weber K, Osborn M. Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years. Am J Pathol 1992; 141: 1003-12.
18. Pujol P, Maudelonde T, Daures J-P, et al. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 1993; 71: 2006-12.
19. Foekens JA, van Putten WLJ, Portengen H, et al. Prognostic value of pS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol 1993; 11: 899-908.
20. Maudelonde T, Khalaf S, Garcia M, et al. Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters. Cancer Res 1988; 48: 462-6.
21. Brouillet JP, Hanslick B, Maudelonde T, et al. Increased plasma cathepsin D concentration in hepatic carcinoma and cirrhosis but not in breast cancer. Clin Biochem 1991; 24: 491-6.
22. Paradiso A, Mangia A, Correale M, et al. Cytosol cathepsin D content and proliferative activity of human breast cancer. Breast Cancer Res Treat 1992; 23: 63-70.
23. Silvestrini R, Veneroni S, Benini E, Di Fronzo G, Daidone MG. p53 and cathepsin D are independent of established prognostic factors in breast cancer. Int J Oncol 1992; 1: 507-12.
24. Ravdin PM, Tandon AK, Allred CA, et al. Cathepsin D by Western blotting immunohistochemistry: failure to confirm comparisons with prognosis in node-negative breast cancer. J Clin Oncol 1994; 12: 467-74.
25. Tan PE, Benz CC, Dollbaum C, et al. Prognostic value of cathepsin D in breast cancer: immunohistochemical assessment and correlation with radiometric assay. Ann Oncol 1994; 5: 329-36.
26. Henry JA, McCarthy AL, Angus B, et al. Prognostic signficance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer 1990; 65: 265-71.
27. Cazin JL, Gosselin P, Boniface B, Boniface M, Demaille A. Expression of pS2 and cathepsin D in breast cancer. Int J Oncol 1993; 2: 1081-4.
28. Gion M, Dittadi R, Leon AE, et al. Comparison between single saturating dose ligand binding assay and enzyme immunoassay for low-salt extractable oestrogen and progesterone receptors in breast cancer: a multicentre study. Eur J Cancer 1991; 27 (8): 996-1002.
29. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 1980; 16: 1513-5.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochem 1976; 72: 248-54.
31. Piffanelli A, Pelizzola D, De Bortoli M, et al. Qualitative assurance for steroid receptor assay in human breast cancer: six years experience of the Italian Committee. Tumori 1985; 71: 589-95.
32. Benraad ThJ, Geurts-Moespot A, Sala M, Piffanelli A, Ross A, Foekens JA. Quality control of cathepsin D measurement by the EORTC Receptor Study Group. Eur J Cancer 1992; 28: 72-5.
33. Mittra I, MacRae KD. A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology? Eur J Cancer 1991; 27 (12): 1574-83.
34. Tubiana M, Koscielni S. Natural history of human breast cancer: recent data and clinical implications. Breast Cancer Res Treat 1991; 18: 125-40.
35. Ingle NG. Prognostic factors in women with node-negative breast cancer. ASCO Proc 1991; 17-22.
36. Foekens JA, Peters HA, Portengen H, Noordegraaf E, Berns EMJJ, Klijn JGM. Cell biological prognostic factors in breast cancer: a review. J Clin Immunoassay 1991; 14: 184-95.
37. Göhring U-J, Ingenhorst A, Crombach G, Scharl A. Kathepsin-D-expression im primären mammakarzinom. Pathologe 1993; 14: 313-7.
38. Veneroni S, Daidone MG, Di Fronzo G, et al. Quantitative immunohistochemical determination of cathepsin D and its relation with other variables. Breast Cancer Res Treat 1993; 26: 7-13.